Recombinant human PDCD5 (rhPDCD5) protein is protective in a mouse model of multiple sclerosis.

BackgroundIn multiple sclerosis (MS) and its widely used animal model, experimental autoimmune encephalomyelitis (EAE), autoreactive T cells contribute importantly to central nervous system (CNS) tissue damage and disease progression. Promoting apoptosis of autoreactive T cells may help eliminate cells responsible for inflammation and may delay disease progression and decrease the frequency and severity of relapse. Programmed cell death 5 (PDCD5) is a protein known to accelerate apoptosis in response to various stimuli. However, the effects of recombinant human PDCD5 (rhPDCD5) on encephalitogenic T cell-mediated inflammation remain unknown.MethodsWe examined the effects of intraperitoneal injection of rhPDCD5 (10 mg/kg) on EAE both prophylactically (started on day 0 post-EAE induction) and therapeutically (started on the onset of EAE disease at day 8), with both of the treatment paradigms being given every other day until day 25. Repeated measures two-way analysis of variance was used for statistical analysis.ResultsWe showed that the anti-inflammatory effects of rhPDCD5 were due to a decrease in Th1/Th17 cell frequency, accompanied by a reduction of proinflammatory cytokines, including IFN-γ and IL-17A, and were observed in both prophylactic and therapeutic regimens of rhPDCD5 treatment in EAE mice. Moreover, rhPDCD5-induced apoptosis of myelin-reactive CD4+ T cells, along with the upregulation of Bax and downregulation of Bcl-2, and with activated caspase 3.ConclusionsOur data demonstrate that rhPDCD5 ameliorates the autoimmune CNS disease by inhibiting Th1/Th17 differentiation and inducing apoptosis of predominantly pathogenic T cells. This study provides a novel mechanism to explain the effects of rhPDCD5 on neural inflammation. The work represents a translational demonstration that rhPDCD5 has prophylactic and therapeutic properties in a model of multiple sclerosis

Deformed Jarzynski Equality

The well-known Jarzynski equality, often written in the form $e^{-\beta\Delta F}=\langle e^{-\beta W}\rangle$, provides a non-equilibrium means to measure the free energy difference $\Delta F$ of a system at the same inverse temperature $\beta$ based on an ensemble average of non-equilibrium work $W$. The accuracy of Jarzynski's measurement scheme was known to be determined by the variance of exponential work, denoted as ${\rm var}\left(e^{-\beta W}\right)$. However, it was recently found that ${\rm var}\left(e^{-\beta W}\right)$ can systematically diverge in both classical and quantum cases. Such divergence will necessarily pose a challenge in the applications of Jarzynski equality because it may dramatically reduce the efficiency in determining $\Delta F$. In this work, we present a deformed Jarzynski equality for both classical and quantum non-equilibrium statistics, in efforts to reuse experimental data that already suffers from a diverging ${\rm var}\left(e^{-\beta W}\right)$. The main feature of our deformed Jarzynski equality is that it connects free energies at different temperatures and it may still work efficiently subject to a diverging ${\rm var}\left(e^{-\beta W}\right)$. The conditions for applying our deformed Jarzynski equality may be met in experimental and computational situations. If so, then there is no need to redesign experimental or simulation methods. Furthermore, using the deformed Jarzynski equality, we exemplify the distinct behaviors of classical and quantum work fluctuations for the case of a time-dependent driven harmonic oscillator dynamics and provide insights into the essential performance differences between classical and quantum Jarzynski equalities.Comment: 24 pages, 1 figure, accepted version to appear in Entropy (Special Issue on "Quantum Thermodynamics"

Draft Genome Sequence of Streptomyces sp. Strain CT34, Isolated from a Ghanaian Soil Sample

Copyright © 2015 Zhai et al. This work was supported by the China “973” program (2012CB721001), the “863” Program (2012AA092201), the National Natural Science Foundation of China (31170467), and the EU FP7 project PharmaSea (312184). K.K., M.J., and H.D. thank the Royal Society–Leverhulme Trust Africa for the financial support (award AA090088) that enabled the sampling of sediments and subsequent isolation of this unique Ghanaian strain.Non peer reviewedPublisher PD

Kirenol attenuates experimental autoimmune encephalomyelitis by inhibiting differentiation of Th1 and th17 cells and inducing apoptosis of effector T cells.

Experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS), is characterized by CNS demyelination mediated by autoreactive T cells. Kirenol, a biologically active substance isolated from Herba Siegesbeckiae, has potent anti-inflammatory activities. Here we investigated effects of kirenol on EAE. Kirenol treatment markedly delayed onset of disease and reduced clinical scores in EAE mice. Kirenol treatment reduced expression of IFN-γ and IL-17A in the serum and proportion of Th1 and Th17 cells in draining lymph nodes. Priming of lymphocytes was reduced and apoptosis of MOG-activated CD4+ T cells was increased in kirenol treated EAE mice. Kirenol treatment of healthy animals did not affect the lymphocytes in these non-immunized mice. Further in vitro studies showed that kirenol inhibited viability of MOG-specific lymphocytes and induced apoptosis of MOG-specific CD4+ T cells in a dose- and time-dependent manner. Kirenol treatment upregulated Bax,downregulated Bcl-2,and increased activation of caspase-3 and release of cytochrome c, indicating that a mitochondrial pathway was involved in kirenol induced apoptosis. Moreover, pretreatment with either a pan-caspase inhibitor z-VAD-fmk or a more specific caspase 3 inhibitor Ac-DEVD-CHO in lymphocytes reduced kirenol induced apoptosis. Our findings implicate kirenol as a useful agent for the treatment of MS

Mesenchymal stem cells and induced pluripotent stem cells as therapies for multiple sclerosis.

Multiple sclerosis (MS) is a chronic, autoimmune, inflammatory demyelinating disorder of the central nervous system that leads to permanent neurological deficits. Current MS treatment regimens are insufficient to treat the irreversible neurological disabilities. Tremendous progress in the experimental and clinical applications of cell-based therapies has recognized stem cells as potential candidates for regenerative therapy for many neurodegenerative disorders including MS. Mesenchymal stem cells (MSC) and induced pluripotent stem cell (iPSCs) derived precursor cells can modulate the autoimmune response in the central nervous system (CNS) and promote endogenous remyelination and repair process in animal models. This review highlights studies involving the immunomodulatory and regenerative effects of mesenchymal stem cells and iPSCs derived cells in animal models, and their translation into immunomodulatory and neuroregenerative treatment strategies for MS

Fake one-time pad cannot be used to improve the efficiency of quantum communication

Two misuses of one-time pad in improving the efficiency of quantum communication are pointed out. One happens when using some message bits to encrypt others, the other exists because the key bits are not truly random. Both of them result in the decrease of security. Therefore, one-time pad should be used carefully in designing quantum communication protocols.Comment: 6 pages, no figure

Threshold quantum cryptograph based on Grover's algorithm

Grover's operator in the two-qubit case can transform a basis into its conjugated basis. A permutation operator can transform a state in the two conjugated bases into its orthogonal state. These properties are included in a threshold quantum protocol. The proposed threshold quantum protocol is secure based the proof that the legitimate participators can only eavesdrop 2 bits of 3 bits operation information on one two-qubit with error probability 3/8. We propose a scheme to detect the Trojan horse attack without destroying the legal qubit.Comment: 7 pages, 1 figure